Abstract: Background: Several tumor entities including brain tumors aberrantly overexpress intermediate conductance Ca 2+ activated K Ca 3.1 K + channels. These channels contribute significantly to the transformed phenotype of the tumor cells.
INTRODUCTION
K Ca 3.1 (SK4, IK Ca , KCNN4) is a Ca 2+ -activated K + channel (for review on the biophysics of IK Ca see [1] in this special issue on K Ca 3.1 channels and glioblastoma) which was first described functionally more than half a century ago by the Hungarian physiologist György Gárdos [2] who identified K Ca 3.1 as the K + conductance in human red blood cells that mediates the efflux of KCl and isoosmotically obliged H 2 O together with a Cl -permeability and aquaporines. The resulting red blood cell shrinkage is paralleled by the morphological transition of the discoid cells into echinocytes. Meanwhile, several physiological and patho-physiological functions have been attributed to the erythrocytic K Ca 3.1 channel. Among those are induction of red blood cell apoptosis (referred to as eryptosis) [3, 4] and irreversible sickling of homozygous HbS/HbS erythrocytes [5] . Therefore, K Ca 3.1 channel inhibitors such as senicapoc have been tested in *Address correspondence to this author at the Department of Radiation Oncology, University of Tübingen, Tübingen, Germany; Tel: +49-(0)7071-29-82183; E-mail: stephan.huber@uni-tuebingen.de clinical trials for their capability to prevent crises of sickle cell anemia patients. These and further trials showed that senicapoc accumulated in the plasma to effective plasma concentrations regarding K Ca 3.1 channel inhibition and that senicapoc was well tolerated indicating that K Ca 3.1 channels are druggable therapy targets [6] in this special issue on K Ca 3.1 channels and glioblastoma.
In addition to erythrocytes, a variety of cell types in different organs express K Ca 3.1 channels. For instance, in epithelial cells of the colon, K Ca 3.1 contributes to transepithelial fluid secretion [7] . Other cell types include vascular smooth muscle and endothelial cells where K Ca 3.1 regulates vasodilatation [8] or Na + transport across the blood brain barrier [9] . Beyond the classical physiological functions, K + channels have been identified to act within biochemical signaling cascades (for review see [10] ). As an example, K effector proteins that contribute to mitogenic signaling. Mechanistically, activated SGKs attenuate removal of K + channels from the plasma membrane and, hence, increase their surface expression. Enhanced activity of plasmalemmal K + channels in turn, is required to stabilize the membrane potential and to maintain the electrochemical driving force for Ca 2+ [13] . Along those lines, proliferation of activated T lymphocytes has been demonstrated to depend critically on K Ca 3.1 activity suggesting that K Ca 3.1 electrosignaling is a regulatory element of the adaptive immune system [14] . Notably, K Ca 3.1 functions also in brain tumor-associated microglia pointing to an immunomodulating effect of any K Ca 3.1-targeting therapy [15] in this special issue on K Ca 3.1 channels and glioblastoma.
In addition to mitogenic signaling, K Ca 3.1 channels in the inner mitochondrial membrane have been proposed to modulate mitochondrial function in colon cancer cells [16, 17] . In pancreatic cancer cells, mitochondrial K Ca 3.1 channels have been suggested to regulate oxidative phosphorylation [18] . Likewise, an adapting function in metabolism has been attributed to plasmalemmal K Ca 3.1 channels. In genotoxically stressed lung adenocarcinoma cells, K Ca 3.1 channel activation [19] parallels increase in glucose uptake by Na + -coupled cotransport [20, 21] suggesting that K Ca 3.1 increases/sustains the driving force for Na + -coupled glucose fueling. In addition, mitochondrial K Ca 3.1 channels have been proposed to contribute to apoptosis induction in melanoma cells [22, 23] . Plasmalemmal K Ca 3.1 channels have been identified in human D54 glioblastoma cells to contribute to apoptotic cell volume decrease triggered by the intrinsic but not extrinsic pathway [24] . In summary, these studies indicate the functional significance of K Ca 3.1 in key cell biological and metabolic processes. The present article aims to review the published in vitro data on K Ca 3.1 function in tumors and in particular in glioblastoma cells. Beyond that, this article provides original data on the role of K Ca 3.1 in therapy resistance of glioblastoma stem cells. 47, 48] . Arresting the cell cycle is crucial for repair of DNA damages, in particular of DNA double strand breaks. Entry into mitosis with residual DNA double strand breaks leads to chromosome aberrations eventually resulting in cell death (mitotic catastrophe).
K Ca 3.1 Channels Control Cell Cycling in Glioblastoma Cells
In a previous study of our group, pharmacological inhibition or knockdown of K Ca 3.1 impaired cell cycle control and G 2 /M cell cycle arrest in irradiated but not in control T98G glioblastoma cells, suggesting a specific function of K Ca 3.1 in DNA damage response [38] . Accordingly, targeting of K Ca 3.1 with TRAM-34 increased the number of residual γH2AX foci as a surrogate marker of unrepaired, residual DNA double strand breaks in that study [38] . In parallel, TRAM-34 attenuated clonogenic survival of irradiated parental and Mock-transduced T98G cells as well as of U-87MG glioblastoma cells. In contrast, a T98G clone stably expressing K Ca 3.1 shRNA was not radiosensitized by TRAM-34 and exhibited a lower radioresistance than the Mock-transduced T98G cells [38] . Vice versa, experimental up-regulation of K Ca 3.1 expression in U251 glioblastoma cells conferred radioresistance and rendered the cells sensitive to TRAM-34 in colony formation assays [10] . Similarly, TRAM-34 has been shown to force G 2 /M cell cycle progression in GL261 glioma cells treated with the DNA-alkylating drug temozolomide probably through cdc2 dephosphorylation which facilitates apoptotic cell death and impairs clonogenic survival [37] . Combined, these data clearly indicate a radio-and chemotherapy-protecting function of K Ca 3.1 in glioblastoma cells. Moreover, these results demonstrate that K Ca 3.1 may act as integrated signaling module within biochemical signal transduction pathways.
K Ca 3.1 Channels Foster Brain Infiltration of Glioblastoma Cells
Beyond electrosignaling in cell cycle control, K Ca 3.1 plays a pivotal role in the programming and/or mechanics of cell migration and invasion into the brain parenchyma [32, 34, 36, 37, 49] (for review also see [15] in this special issue on K Ca 3.1 channels and glioblastoma). Cell migration is motorized by volume decrease at the cell rear and volume expansion of the invadipodium that result in a directed movement along the rear/invadipodium axis. Volume changes on both cell poles are generated by net uptake/efflux of electrolytes which is accompanied by concordant fluxes of isoosmotically obliged H 2 O [50] . Glioblastoma cells, in particular, invade the brain parenchyma by migration along blood vessels and neurofibres using them as tracks. By doing so, glioblastoma cells have to squeeze through narrow interstitial spaces which requires highly efficient local cell volume control [51] .
Functional K Ca 3.1 channel expression has been demonstrated by patch-clamp on-cell recording at the cell rear of T98G, U-87MG [38] , and U251 cells [10] . In addition, immunohistochemistry data indicate K Ca 3.1 channel protein expression at the invadipodium of D54 human glioma cells [36] . The K Ca 3.1 channel blocker TRAM-34 reportedly inhibits both, fetal calf serum (FCS)-induced Ca 2+ oscillation and FCS-stimulated chemotaxis in transwell migration assays in a subpopulation of U-87MG glioblastoma cells [32] . Similarly, TRAM-34 inhibits bradykinin-induced chemotaxis of human D54 glioma cells [36] . In addition to cell migration, conditional K Ca 3.1 knockdown and/or TRAM-34 reportedly inhibit the in situ invasion of U251 cells and primary glioblastoma neurosphere cultures into brain slices [34] . Likewise, TRAM-34 has been documented to inhibit migration and invasion of GL261 glioma cells in wound healing and Matrigel invasion assays, respectively [37] . Taken together, these in vitro experiments clearly indicate the functional significance of K Ca 3.1 channels for glioblastoma cell migration and brain invasion.
K Ca 3.1 Channels are Upregulated in Glioblastoma Stem Cells
Glioblastoma stem-like cells have been proposed to constitute the most therapy-resistant and most invasive subpopulation of glioblastoma cells responsible for brain infiltration and therapy failure [52] [53] [54] [55] . Notably, K Ca 3.1 channels are overproportionally up-regulated in the CD133 stem cell marker-positive subpopulation of gliobastoma cells as demonstrated in the U-87MG line grown in stem cell-enriched neurospheres and in the 2B5 subclone of FCN9 cells. In stem cell-enriched U-87MG and 2B5 cells, TRAM-34 strongly attenuated invasion as assessed by fibronectin-coated Boyden chamber assay [49] suggesting that migration of glioblastoma stem cells crucially depends on K Ca 3.1 function. Along those lines, in CD133 + stem cell-enriched primary neurosphere cultures of human glioblastoma specimens, only temozolomide in combination with TRAM-34 was capable to inhibit DNA synthesis as measured by [
3 H]-thymidine incorporation [37] . In addition to K Ca 3.1 function in cancer stem cells, K Ca 3.1 activity has been reported in normal mesenchymal stem cells [56, 57] and neuronal precursor cells [58] . Combined, these data point to a specific K Ca 3.1 function in normal and glioblastoma stem cells.
Stem Cells of Molecular Glioblastoma Subtypes
Human glioblastoma are classified in four molecular subgroups referred to as classical, mesenchymal, proneural and neural [59] . Mesenchymal and proneural types of glioblastoma stem cells have been identified which present gene signatures similar to the mesenchymal and the proneural molecular glioblastoma subgroup, respectively. Importantly, mesenchymal stem cells have been suggested in some studies to exhibit a more aggressive phenotype and higher radioresistance than proneural stem cells [60, 61] . Analysis of clinical data from glioblastoma patients, in contrast, suggests, that tumors with mesenchymal expression profiles predict for longer survival than proneural expression profiles [59, 62] .
Mesenchymal cancer stem cells have been demonstrated to highly upregulate the mesenchymal aldehyde dehydrogenase isoform 1A3 (ALDH1A3) [60, 63, 64] . Subjecting glioma cells to ionizing radiation induces up-and downregulation of markers associated with mesenchymal and proneural properties, respectively. Most importantly, radiationinduced upregulation of mesenchymal markers depend on ALDH1A3 function [60] . Moreover, in neuroblastoma, ALDH1A3 knock-out reduces clonogenicity and selfrenewal capacity [65] . In head and neck squamous cell carcinoma, knock-down of ALDH1A3 decreases radioresistance [66] . In addition, ALDH1A3 downregulation reduces resistance to chemotherapy in malignant pleural mesothelioma cells [67] . Finally, in glioma ALDH1A3 knockdown suppresses the ability of tumor invasion [64] . Together, these data clearly indicate that the aggressiveness of mesenchymal cancer stem cells strongly relies on ALDH1A3-mediated signaling.
K Ca 3.1 Channels Contribute to the Malignancy of Mesenchymal Glioblastoma Stem Cells
In addition to reviewing the literature, the present article aims to compare K Ca 3.1 expression and function between mesenchymal and proneural glioblastoma stem cells. To this end, human resection specimen-derived glioblastoma cells were grown under cancer stem cell-enriching culture conditions and K Ca 3.1 mRNA abundance was determined in dependence on the expression of stem cell markers. In addition, the functional significance of K Ca 3.1 for radioresistance was defined by analyzing repair of DNA double strand breaks in dependence on K Ca 3.1 inhibition.
Cell suspension of individual glioblastoma resection specimens (n = 13) grew in stem cell medium either as floating globular spheres, as attached spheres, as sphere-like attached layer, or as adherent monolayer with spotted spheroid-like uprisings (Fig. 1A) .
Scoring these culture phenotypes from 1 (floating spheroids) to 4 (monolayer) and plotting these scores against the mRNA abundances of the pluripotent stem cell marker Notch1 [68] , the mesenchymal marker ALDH1A3, the neu-ral stem cell marker Nestin [69] , the neuronal precursor marker CXCR4 [70] and K Ca 3.1 did not disclose any association of the growth phenotype with the abundance of Notch1 or Nestin (Fig. 1B) . In contrast, ALDH1A3 and K Ca 3.1 showed a weak positive correlation (Pearson correlation coefficient PC = 0.44 and 0.48, respectively) while CXCR4 correlated moderately in a negative manner (PC = -0.53) with the morphology score (Fig. 1B) . This might hint to a more spheroid phenotype of CXCR4-positive proneural and a more adherent growth phenotype of mesenchymal glioblastoma stem cells and K Ca 3.1-expressing cells.
Next, we directly analyzed the K Ca 3.1 mRNA abundance in the primary glioblastoma cultures in dependence on stem cell marker expression. The data given in (Fig. 2) suggest a moderate negative correlation of K Ca 3.1 with CXCR4 (PC = -0.54) and Nestin (PC = -0.64) as well as a weak positive . For immunofluorescence microscopy 1500 cells/well were seeded on a Millicell EZ SLIDE 8-well glass (Merck Millipore, Tullagreen, Ireland) and grown for 7 days, irradiated in the presence or absence (DMSO vehicle) of TRAM-34 (1 µM, Sigma-Aldrich, Deisenhofen, Germany) with 0, 4 or 8 Gy with 6 MV photons using a linear accelerator at a dose rate of 4 Gy/min, further incubated for 24 h with TRAM-34 and vehicle alone, respectively, and fixed with 3.7% formaldehyde for 15 min at 21°C followed by three washing steps with PBS. Next, cells were permeabilized for 10 min at 21°C with 0.1% Triton-X 100 in PBS followed again by three washing steps with PBS. Cells were probed against γH2AX and K Ca 3.1 protein using anti-γH2AX antibody (monoclonal mouse, Merck Millipore) and the anti-K Ca 3.1 antibody (polyclonal rabbit; Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) in 1:1000 and 1:50 dilution, respectively, and antibody binding was visualized with the Tyramide Signal Amplification Kits for mouse and rabbit primary antibodies (Molecular Probes, Eugene, Oregon, USA). Prior to mounting, nuclei were counterstained with DAPI (Sigma-Aldrich).
(The color version of the figure is available in the electronic copy of the article).
correlation with Notch1 (PC = 0.48) and a highly positive correlation with ALDH1A3 (PC = 0.82) hinting to an upregulation of K Ca 3.1 in mesenchymal stem cell-enriched glioblastoma.
To determine the functional significance of K Ca 3.1 for the radioresistance of mesenchymal stem cell-enriched glioblastoma cultures, residual γH2AX foci were counted as a surrogate of unrepaired DNA double strand breaks 24 h after irradiation with 0, 4 or 8 Gy. A primary culture with high ALDH1A3 and K Ca 3.1 expression (Fig. 3A, left) and -for reference -a culture with low ALDH1A3 and K Ca 3.1 expression (Fig. 3A, right) were treated during irradiation and the following 24 h-incubation period with either vehicle alone or TRAM-34 (1 µM). Residual nuclear γH2AX foci were visualized by enhanced immunofluorescence microscopy (Fig. 3B) and foci number was plotted against the radiation dose (Fig. 3C and 3D) . The slope of the foci number/radiation dose curve has been suggested to reflect the intrinsic radiosensitivity of the tumor cells [71] and was significantly steeper in cells with low as compared to those with high ALDH1A3 expression (compare open circles between Fig. 3C and 3D) . Importantly, TRAM-34 radiosensitized only the culture with high ALDH1A3 expression (Fig. 3C , closed triangles) while having no effect in the low ALDH1A3-expressing cells (Fig. 3D, closed triangles) . Accordingly, TRAM-34 significantly increased the number of residual γH2AX foci 24 h after irradiation with 8 Gy in the high ALDH1A3-expressing but not in the low ALDH1A3-expressing culture (Fig. 3E) . Combined, these experiments confirm our previous data acquired in cell lines on the K Ca 3.1-mediated radioresistance in glioblastoma. Moreover, the present experiments suggest that K Ca 3.1-mediated radioresistance is largely confined to mesenchymal glioblastoma stem cells.
CONCLUDING REMARKS
The in vitro data on K Ca 3.1 Ca 2+ -activated K + channels suggest multiple biological functions of these channels for tumor cells. In particular in glioblastoma, K Ca 3.1 has been identified as a key regulator of glioblastoma cell migration and DNA damage response suggesting that K Ca 3.1 promotes brain infiltration and intrinsic radioresistance in vivo. The original data set of the present article suggests an upregulation of K Ca 3.1 especially in the mesenchymal subtype of glioblastoma stem cells. In vivo, induction and maintenance of the highly malignant "stemness" phenotype have been proposed to depend on the reciprocal interaction of glioblastoma cells with endothelial cells in perivascular stem cell niches [72] [73] [74] . In this context, CD133
+ glioblastoma stem cells have been shown to exhibit higher radioresistance than CD133 -cells after xenografting into mouse brain pointing to an induction of radioresistance by the tumor microenvironment [75] . Chemotaxis [32, 36] including SDF1-induced chemotaxis [39] reportedly depends on K Ca 3.1. Moreover, formation of the perivascular stem cell niche requires SDF1/CXCR4 signaling [76] . Therefore, one might speculate that beyond conferring intrinsic radioresistance, K Ca 3.1 also contributes to SDF1/CXCR4-guided homing of glioblastoma cells to perivascular stem cell niches and to the acquisition/maintenance of the radioresistant glioblastoma stem cell phenotype.
Hence, K Ca 3.1 might be a promising pharmacological target to prevent the induction and/or maintenance and to attenuate the radioresistance of in particular mesenchymal glioblastoma stem cells as suggested by the present article. As pointed out in the INTRODUCTION section, K Ca 3.1 is druggable and patients especially with the mesenchymal molecular subtype of glioblastoma might benefit from K Ca 3.1 targeting in combination with fractionated radiotherapy. For such a therapy strategy, the immune-modulating action of systemic K Ca 3.1 targeting must be taken into account. As a matter of fact, K Ca 3.1 targeting has been demonstrated to induce a switch of glioblastoma infiltrating microglia/macrophages towards a pro-inflammatory, anti-tumor phenotype [77] which is thought to improve the therapy outcome.
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